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Effects of recombinant human erythropoietin on HLA sensitization and
cell mediated immunity. Highly presensitized patients wait longer for a
renal allograft than unsensitized patients and have a poorer allograft
survival rate. Repeated blood transfusions have been implicated in the
induction and maintenance of sensitization. To determine the effect of
recombinant human erythropoietin (rHuEPO) therapy on five transfu-
sion dependent, highly sensitized adolescents on dialysis, we serially
measured percentage panel reactive antibody (%PRA) levels, titers of
identifiable discrete anti.HLA Class I antibody specificities, and non-
specific indices of cellular immunity before and following initiation of
rHuEPO therapy. Although four of the five patients had previously
rejected at least one renal allograft, the removal of chronic antigenic
stimulation from blood transfusions led to a marked reduction in
anti-HLA antibody titers to recognizable private and public specificities(P < 0.001) and a reduction of mean %PRA from 80% to 56% (P <
0.05). Each patient demonstrated a reduction of two or more dilutions
to at least two anti-HLA antibody specificities. A control group of five
patients matched for age, transfusion dependence and sensitization
status demonstrated no change during a comparable time interval. PHA
responsiveness decreased significantly in the rHuEPO group whereas
autologous and allogenic mixed lymphocyte response, spontaneous
blastogenesis and T-ceIl subsets did not. These data indicate that in
highly sensitized dialysis patients rHuEPO may lead to decreased
sensitization, shorter waiting time on dialysis and possibly improved
allograft survival rates.
In patients on dialysis, repeated exposure to foreign HLA
antigens can result in a highly presensitized state. Humoral
presensitization is measured by reacting patient serum against a
panel of T lymphocytes from normal donors using the comple-
ment dependent cytotoxicity (CDC) technique [1]. The result is
expressed as the percentage panel reactive antibody (%PRA).
For more than a decade, highly presensitized patients have
made up an ever-increasing proportion of those awaiting renal
transplantation [2]. A potential recipient's serum must be
devoid of antibody against the donor's Class I HLA antigens at
the time of transplantation in order to avoid hyperacute rejec-
tion [3]. The waiting time for such a suitable crossmatch-
negative donor kidney increases linearly with the degree of
sensitization [4]. The median waiting time is more than four
years if the PRA is > 95% [5].
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Presensitization also adversely impacts allograft survival.
First transplants with a PRA > 50% have a one year graft
survival rate 8% lower than unsensitized patients, while re-
transplants with a PRA> 10% have a 10% lower graft survival
rate than similar unsensitized recipients [5]. This may be due to
the adverse effects of the anti-HLA antibodies upon allograft
outcome. Alternatively, sensitization could be an index for
augmented T cell-mediated immune activity. A number of
studies have suggested that allograft outcome is affected by the
strength of the non-specific cell-mediated immune response [6,
7]. High levels of sensitization could thus signify a strong
immune-responder status.
Patients may be sensitized by three mechanisms: prior preg-
nancy; previous allograft or blood transfusions. The relative
contribution of each of these mechanisms to the initiation and
maintenance of sensitization is controversial. Alone, blood
transfusions may be less important [8], but following a failed
transplant [2, 9] or a previous pregnancy [8], blood transfusions
take on a greater importance in initiating sensitization. What is
not clear, however, is the contribution of continuing blood
transfusions to the maintenance of the sensitization.
Recently, recombinant human erythropoetin (rHuEPO) has
been shown to reverse the anemia of chronic renal failure [10].
It appears that the need for blood transfusions may be totally
obviated by rHuEPO in many dialysis patients. While the
avoidance of blood transfusion should eliminate initiation of
anti-HLA sensitization in patients without a previous preg-
nancy or prior allograft, the effect that such avoidance would
have on an established state of presensitization is unknown. In
particular, it is not clear what effect rHuEPO treatment and
subsequent transfusion avoidance would have on the degree of
anti-HLA sensitization in patients with established levels of
presensitization, although Braun et al noted that rHuEPO
therapy facilitated only some highly sensitized patients to
experience a decrease in %PRA [11]. There are no studies on
the effect of rHuEPO therapy and transfusion avoidance on the
T cell immune response in dialysis patients with established
anti-HLA sensitization.
We recently performed a preliminary study of rHuEPO
treatment in five highly presensitized adolescents undergoing
contznuous cycling peritoneal dialysis (CCPD) [12]. Because of
the paucity of data concerning transfusion elimination in highly
presensitized dialysis patients, we prospectively studied both
the humoral and T cell-mediated immuneresponses that appear
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Rejected at 8 yrs
—
Rejected at I mo & 4 mo
Rejected at 6 yrs
Rejected at 2 yrs
Mean 41
Abbreviations are: MCD, medullary cystic disease; FSGS, focal segmental glomeruloscierosis; RPGN, rapidly progressive glomerulonephritis.








































Rejected 3 mo & never functioned
—
Never functioned
Rejected, 1 yr & 10 yr
Rejected, 1 yr
Mean 32 7.2
Abbreviations are: GN, glomerulonephritis; IPKD, infantile polycystic kidney disease.
important to renal transplant outcome. To fully probe the
significance of transfusion avoidance, we examined not only
serial PRA levels but also the strength of discrete anti-HLA
Class I antibody specificities, an approach heretofore not re-
ported. Our studies indicated that transfusion withdrawal was
associated with a significant decrement in the strength of
anti-HLA antibodies in all patients even when the breadth of
the antibody response, that is, the %PRA, did not change
dramatically. We also observed a down-regulation of nonspe-
cific T cell function following avoidance of transfusions.
Methods
Patients
Five transfusion dependent adolescents, aged 12 to 18 years,
undergoing CCPD comprised the study group. Patient data are
presented in Table 1. Inclusion criteria, rHuEPO dosage and
therapeutic outcome have been reported previously [121. Four
of the five patients had rejected at least one prior renal allograft.
Prior to initiation of rFIuEPO, the study patients received a
mean of 41 blood transfusions (range 23 to 77), over a mean of
46 months (range 21 to 96 months). Each patient had a PRA of
at least 40%. rHuEPO was administered for a mean of 13.6
months (range 9 to 18 months). In four of the five patients,
rHuEPO was discontinued at the time of renal transplantation;
the fifth patient (#V) continues to receive rHuEPO while on
dialysis. Following an observation period of at least three
months, baseline studies were obtained and rHuEPO begun.
Immunological studies were performed at three to six month
intervals. Final immunological studies were performed imme-
diately prior to renal transplantation in four patients and at the
arbitrary conclusion of the study (15 months) in the patient
remaining on dialysis. rHuEPO was supplied by Amgen Inc.,
Thousand Oaks, California, USA.
The control group was five patients retrospectively matched
for age, sensitization status, transfusion requirement and trans-
plant history. Their clinical data are presented in Table 2. They
had received a mean of 32 blood transfusions (range 23 to 46),
over a period of 43 months (range 24 to 84 months). Humoral
assays were performed in both the study and control group;
cellular assays were performed in the study group only. The
study was approved by The UCLA Human Subjects Protection
Committee and written informed consent was obtained prior to
initiation of the study.
Immune monitoring—Immoral
At three month intervals, aliquots of sera were obtained,
frozen at —70°C and stored for assays of humoral sensitization.
Anti-Class I HLA antibodies were assayed by the standard long
incubation CDC assay, as modified in our laboratory, against a
40 member T-lymphocyte panel [1]. All reagents were obtained
from Gibco (Santa Clara, California, USA). Serial dilutions
were made with McCoy's 5A medium with 20% fetal calf
serum. Briefly, 1 pi of sera or a dilution thereof was aliquoted
into four replicate wells of oiled microtiter trays. One 1d of
T-lymphocytes (previously separated by negative selection
using the H4 monoclonal antibody from One Lambda, Los
Angeles, California, USA) was adjusted to 3 x 106 cells/mI,
added to each well and incubated at 20°C for 60 minutes. Five
sl preselected rabbit complement (Pel Freeze, Brown Deer,
Wisconsin, USA) was added and incubated for 120 minutes.
Following three minute eosin staining and formalin fixation,
trays were read independently by at least two of the authors.
Significant cytotoxicity was defined as > 50% of cells killed in
a given well. The %PRA was expressed as the percentage of the
T lymphocyte panel killed in the CDC assay by the undiluted
test serum [1].
Fig. 1. Anti-HLA class I antibody as measured by the %PRA. The interrupted line indicates the mean. (a) Control patients at the start and finish
of the observation period (mean 18 months) demonstrated no significant change in mean %PRA; 86 15% at the start and 86 9.5% at the finish
(P > 0.5). (b) Patients treated with rHuEPO demonstrated a mean %PRA at the initiation of the rHuEPO of 80 24% that fell to 56 40.6% at
the termination of the study (P < 0.05). Symbols are patient number: 1(0); II (El); III (s); IV (); V (•).
For each patient's serum the anti-HLA Class I specificities
were determined using the HKB® Software Package installed
on an IBM computer, using a correlation coefficient (r value)
cutoff of> 0.5 above which a specificity could be assigned [13].
If undiluted sera were too broadly reactive to assign identifiable
specificities, dilutions were used to identify all of the strong
specificities remaining after dilution [14]. After all specificities
were determined, the titer of each anti-HLA class I antibody
specificity was defined as the highest dilution killing < 50% of
the cells expressing that antigen, that is, the dilution at which
there was no significant killing. The titering studies were
performed simultaneously on all sera to minimize interassay
variation.
Immune monitoring—cellular
Isolation of peripheral blood mononuclear cells. At three to
six month intervals 12 ml of heparinized blood was obtained
from each of the study patients. Peripheral blood mononuclear
cells (PBM) were sterilely isolated by standard density gradient
centrifugation using Histopaque (sg 1.077, Sigma, St. Louis,
Missouri, USA) [15], washed twice in Hank's Balanced Salt
Solution (HBSS) and resuspended at 106 cells/ml in RPMI 1640
with glutamine 2 mmolar, 10 mmolar HEPES buffer, 10%
human AB serum, penicillin 50 z/ml and streptomycin 50 g!ml
(Complete RPM!).
PHA stimulation. The mitogen, phytohemagglutinin (PHA;
Dilco, Detroit Michigan, USA), was dissolved in complete
RPMI. io Responder cells were cultured in a total volume of
200 d of PHA at final concentrations of 5, 10 and 20 g!ml in
five replicate wells in a 5% CO2 37°C incubator. At 72 hours a
pulse of 1.25 sCu!well 3H thymidine was added in 50 sl
complete RPM!. After incubation for an additional 18 hours,
incorporated radiolabel was measured by harvesting using a
Multiple Automated Harvesting Unit (Titertek), dried, then
counted with a Beckman Liquid Scintilation Counter using
Omnifluor (DuPont, Boston, Massachusetts, USA) in toluene
as the scintilator. Results were expressed as the total counts!
minute (CPM) SD.
Allogenic mixed lymphocyte reaction (MLR). The MLR was
assayed using autologous as well as allogenic cell stimulators.
Allogenic stimulator cells from a frozen donor pool of nine
members were selected to represent a broad array of class II
antigens. Cells were thawed, washed and suspended at 106
cells/ml in complete RPM!. Stimulator cells were irradiated
with 2000 rads from a Gammacel (Atomic Energy Canada)
'35Cesium source. One hundred microliters of stimulator cells
were co-cultured with 100 i1 responder cells for 120 hours; the
cells were then pulsed, harvested and counted as described in
the previous section.
Spontaneous blastogenesis and T cell subsets. The assays for
spontaneous blastogenesis and T cell subsets have been de-
scribed previously [16].
Statistical analysis
Statistical analysis was performed using Wilcoxon's signed-
rank test for non-parametric data (titers) and the paired t-test
for %PRA and mitogen response from the Statview® Software
package. Titers were analyzed after inverse logarithmic trans-
formation.
Results
rHuEPO therapy resulted in correction of anemia in each of
the five patients [12]. Four of the five patients received no
subsequent transfusions. The fifth (#V) received a transfusion
for surgical bleeding nine months after starting rHuEPO.
For a mean of 15 months (range 4 to 36 months) prior to
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Fig. 2. Changes in specific anti-HLA titers. Each line represents a single specificity from a single patient and is labelled with the control patient
# first and then the HLA Class I specificity. The interrupted line shows the mean titer. (a) In control patients the mean titer remained at (1/32)
during the observation period (F> 0.6 by Wilcoxon). (b) In rHuEPO treated patients the mean titer fell from 1/32 to 1/8 (P = 0.003 by Wilcoxon).
initiation of rHuEPO therapy the patients had maintained a
%PRA within 10% of the value at the start of rHuEPO
therapy. Figure 1 compares the baseline PRA at the start of
rHuEPO therapy with the PRA after a mean of 13.6 months of
rHuEPO therapy. There was a reduction in PRA (Fig. 1B) from
the baseline mean value of 80 24% to a mean of 56 40.8%
at the termination of the study (P < 0.05).The one patient (#V)
who maintained a PRA in the 97 to 100% range (Fig. 1B) was the
patient who required a transfusion. The control patients con-
tinued to require transfusions and experienced no change in
%PRA (Fig. 1A). At the beginning of the observation period,
the mean PRA was 86 15% and after a mean of 18 (range 8 to
21) months it was 86 9.5% (P NS).
All Class I anti-HLA antibody specificities and titers were
identified, measured and followed in the sera of the rHuEPO
and the matched control patients. Each of the five rHuEPO
patients showed a reduction of two or more dilutions of at least
two anti-HLA antibody specificities. The mean titer of all of the
identifiable Class I anti-HLA antibody specificities in the five
study patients fell significantly over the course of the study
(Fig. 2B). Even patients #111 and #V, whose %PRA remained
> 80% throughout the course of the study, experienced a titer
decrement of two or more dilutions in four of six specificities
identified. In the five control patients, 11 Class I anti-HLA
antibody specificities were identified in baseline or follow-up
studies. As shown in Figure 2A, there was no consistent pattern
on change in the titers of these specificities; the titer of three
specificities rose, five specificities declined and three remained
unchanged. Overall, there was no dominant pattern and no
change in the mean titer of the identifiable specificities during
the observation period in the control patients (Fig. 2A) (P >
0.6). At the end of the study, only 2 of the 11 identifiable
specificities in the control patients were at or below titers of 1:4.
By contrast, 7 of the 12 identifiable specificities in the study
patients had fallen to 1:4 or below.
The PBM of rHuEPO patients demonstrated a significant
decrease in PHA responsiveness during the study period. This
was true at all concentrations of PHA tested. A representative
set of studies for a PHA concentration of 10 tg/ml is shown in
Figure 3. At a PHA concentration of 5 gIml, the mean value
fell from 5.6 1.8 x l0 CPM at the start of the study to 3.0
1.8 x lO CPM at the conclusion; at a PHA concentration of 10
pgIml, the mean value fell from 6.2 1.9 x iO CPM to 3.9
1.9 x io CPM (Fig. 3) and at a PHA concentration of 20
g!ml, the mean value fell from 5.7 1.1 x i0 cpm to 4.0 1.1
x l0 CPM (P < 0.05 for each PHA concentration level). There
were no significant trends in the other assays of cellular
immunity.
Four of the five patients in the rHuEPO group terminated the
study at the time they received a cadaveric renal allograft. None
has yet lost a graft because of rejection. The renal transplants of
patients #1, #111 and #IV are functioning well with a serum
creatinine level of 1.4, 1.0 and 0.6 mg/dl at 21, 15 and 8 months,
respectively, after transplant. Patient #11 received a cadaveric
renal allograft and four months later attained a serum creatinine
level of 1.5 mg/dl. Recurrent focal segmental glomerulosclerosis
with debilitating nephrotic syndrome required discontinuation
of immunosuppression, return to CCPD and allograft emboliza-
lion. During the observation period of 18 months no control
patient received a kidney transplant. In the time since the
termination of the study (mean 13 months) only one patient
(Ill-c) has received a kidney. It would have been interesting to
determine whether the transplant recipients had historical pos-
itive crossmatches against their donors. Unfortunately, there
were no viable donor lymphocytes available for us to make this
determination.
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observation
period
Fig. 3. Representative example of PHA induced proliferative response
at initiation and termination of rHuEPO study. Proliferation was
assessed by uptake of a 3H thymidine pulse and is reported in
counts/minute (CPM) x l0. The interrupted line demonstrates the
meanCPM fell from 6.2± 1.9 X iO to 3.9± 1.9 X 105 CPM (P<O.05).
Symbols are patient number: () I; (0) U; (C) III; (•) IV; (C) V.
Discussion
The importance of blood transfusions in the genesis and
maintenance of the highly presensitized state has been intensely
debated, particularly in light of the finding that blood transfu-
sions improved allograft survival rates in a dose-dependent
manner, that is, increasing numbers of transfusions yielded
increasing improvement in graft survival rates [17]. More re-
cently, two developments appear to have dramatically changed
the immunological conditioning requirements for those awaiting
transplantation. The first is the report by Opelz and the Collab-
orative Transplant Study documenting that pre-transpiant
transfusions have lost their primacy as a conditioning regimen
[18]. With improvements in post-transplant management and
immunosuppression, it now appears that non-transfused recip-
ients have a graft survival rate comparable to that reported for
transfused recipients. The second is the clinical availability of
rHuEPO. rHuEPO can eliminate the need for blood transfu-
sions in patients on dialysis [10]. In the future, transfusion-
induced hyperimmunization should diminish as fewer patients
require multiple transfusions.
There are still a large number of hyperimmunized patients
currently awaiting renal transplantation [5], and it is unclear
how rHuEPO therapy and the avoidance of transfusions will
affect them. Deierhoi et al [19] reported a 36 month follow-up of
92 patients, the majority of whom had lost at least one previous
renal transplant. They found that the most important risk factor
for sustained high levels of anti-HLA sensitization was ongoing
transfusions. Norman et al [4] examined the pattern of sensiti-
zation that followed five prospective transfusions in non-sensi-
tized untransplanted adults. All but one of the patients who
became sensitized with a PRA > 45% demonstrated a reduction
after transfusions were curtailed; this reduction occurred over
an interval of a few months, and there was complete loss of
sensitization by 9 to 18 months. Braun et a! [11] followed the
%PRA in 16 patients treated with rHuEPO for a mean of 15.4
months. They concluded that rHuEPO allowed patients with
low %PRA's to maintain their low level, allowed those with
moderate to high %PRA's to experience some fall, but did not
affect the %PRA's of the most highly sensitized patients.
Scornik et a! [20] followed the %PRA of a population of dialysis
patients, some of whom had previously rejected a renal al-
lograft. In spite of not receiving recent transfusions, the %PRA
of the previously transplanted patients changed little over the
observation period, although there was an occasional reduction
in antibody concentration as measured by flow cytometry.
These studies suggest that transfusions are an important
factor in the maintenance of a sustained high %PRA [19] and
that their withdrawal may result in a reduction in the level of
sensitization as measured by the %PRA in a significant propor-
tion of highly sensitized patients [4, II]. Nevertheless, very
highly sensitized patients, particularly those who have rejected
a previous transplant [20], may not experience a decrease in
their %PRA, at least over the time interval studied, in spite of
elimination of transfusions.
The results of the present study demonstrate that rHuEPO
and concomitant avoidance of blood transfusions led to a fall in
%PRA. Indeed, the mean %PRA fell significantly although two
of the most highly sensitized patients had no clinically mean-
ingful %PRA decrease. Our study differed from previous ones
in that, in addition to %PRA, we examined the sera of rHuEPO-
treated and control patients for the titers of discrete Class I
anti-HLA antibody specificities. All of the study patients
showed reductions of identifiable anti-HLA antibody sensitiza-
tion despite the fact that four of the five had rejected at least one
previous transplant. We found a significant titer reduction in at
least two anti-HLA antibody specificities in all five patients
studied. This was true even in the patients with the highest
%PRA's who experienced either no decrement or a negligible
decrement in their level of sensitization. In three of the five
patients, the two falling specificities had some cross reactivity;
therefore it is possible that the actual number of antibody
specificities falling was lower than the 10 of 12 shown in Figure
2B. The control group demonstrates no consistent changes over
a comparable observation period. It could be argued that some
in the rHuEPO group had lower initial levels of sensitization
(that is, %PRA) than the control patients, even though the mean
%PRA values were not statistically different. However, the
results in the three patients (#111, IV and V) with an initial
%PRA of  90% were no different than the results in patients
#1 and II, who had PRA's of 53% and 60%. Our prospectively
studied patient population was small because the Phase I
rHuEPO study was limited to five adolescents. Nevertheless, it
is reasonable to extrapolate from our data that, given enough
time without transfusion, even the most sensitized patients may
reduce their Class I anti-HLA sensitization to the point where a
crossmatch-negative kidney can become available. At first
glance, this latter statement may appear to conflict with the
studies of Braun et al [11] and Scornik et al [20], both of which
described a population of previously transplanted patients who
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sions. However, in both of these studies the authors did not
determine the change, if any, in the strength (that is, titer) of the
antibodies against discrete Class I anti-HLA specificities (al-
though in one study, antibody strength was assessed against a
small number of randomly chosen cells [201). Our finding of
falling titers in all of the rHuEPO patients suggests that the
antibody loss is occurring but cannot be detected over relatively
short observation periods by the somewhat insensitive %PRA.
Reduction in the titers of Class I anti-HLA antibody speci-
ficities will ultimately lead to an increased probability of finding
a crossmatch-negative kidney, even if there is only a reduction
and not a total disappearance. This is because a reduction in
Class I anti-HLA antibody titer, particularly if the antibody in
question is broadly reactive, results in a diminution of activity
against other members of that particular cross-reacting group
[211. Three of our five patients appeared to have a two titer
decrement in at least one broadly reactive anti-HLA antibody
specificity (Patients #'s III, IV and V). Thus our finding would
appear to have important implications for a large number of
highly sensitized dialysis patients awaiting transplantation. If
patients can be maintained transfusion-free for a sufficient
period of time with rHuEPO, it is reasonable to hypothesize
that the frequency of transplantation in highly sensitized pa-
tients could increase dramatically.
In addition to the changes in anti-HLA antibody titers, we
also found that transfusion avoidance was associated with some
evidence of decreased non-specific cell-mediated immunity, as
evidenced by a fall in PHA responsiveness. The natural history
of the PHA response following rHuEPO treatment is important
in view of the studies of Jones et al [6] demonstrating that a high
pretranspiant PHA response is associated with a significantly
poorer short-term renal allograft survival rate than is a low
response. This suggests that the long-term elimination of repet-
itive blood transfusion, and the HLA antigenic stimulation that
can occur with rHuEPO therapy may lead to improved allograft
survival in highly sensitized patients by allowing T cell respon-
siveness to down-regulate.
Plaffi et a! [22] reported significant changes in circulating T
lymphocyte markers consistent with decreased cell-mediated
immune responsiveness after 16 weeks of rHuEPO therapy.
They studied 15 patients and found a statistically significant
decrease in absolute T cell numbers, CD4 (helper) and CD8
(suppressor) cell numbers, as well as in the CD4/CD8 ratio. We
found no significant changes in cellular markers, but this may be
due to the small number of patients studied here and a conse-
quent Type II error. This combined functional and phenotypic
evidence of a change in the cellular immune system combined
with the evidence for a decrease in humoral sensitization,
suggests that rHuEPO administration and the resultant elimina-
tion of chronic HLA stimulation leads to a down-regulation of
immune responsiveness.
With the demonstration by Kerman et al [7] that graft
outcome is dependent on the cellular immune responder status
of the recipient, our findings are important. In this regard, it is
notable that in both the study of Braun et al [11] and our study
of patients receiving rHuEPO therapy, allograft loss from
rejection was minimal. This is remarkable in view of the high
number of highly presensitized patients who received trans-
plants.
The question of whether a high %PRA in itself leads to a poor
allograft survival or is just a marker of a more fundamental
cellular sensitization remains unanswered. Preliminary data
from our laboratory suggest that the highly presensitized state is
accompanied by an augmented lymphocyte response to a pool
of lymphocytes in the MLR [23]. Regardless of the cellular site
at which presentation becomes deleterious for the transplanted
kidney, it is likely that transfusion elimination in the highly
presensitized patient can only be beneficial to subsequent graft
outcome. Indeed, this suggestion has been advanced by others.
Norman et al [4] documented 100% two year graft survival in
patients sensitized to > 45% PRA by prospective blood trans-
fusions who subsequently 'lost' sensitization after transfusions
were discontinued. In this study, the reduction of %PRA was in
response to discontinuing HLA stimulation in the form of blood
transfusions. Another question is whether there is any active
immunological basis for graft outcome improvement in this
setting or whether the effect is solely one of antigenic with-
drawl. In this regard, the very preliminary demonstration in our
laboratory that the sera of some of the rHuEPO patients
showed anti-idiotypic antibody activity against Class I HLA
antibody may be quite germane [24]. Some authors have
presented evidence that the presence of such anti-idiotypic
antibodies may be associated with enhanced graft survival [25].
Although this study was performed in adolescents, there is no
reason to anticipate that the conclusions to be drawn cannot be
extended to highly sensitized patients of any age. We conclude
that rHuEPO treatment in dialysis patients can lead to elimina-
tion of blood transfusions and consequent reduction in chronic
HLA antigenic stimulation. In the dialysis patient this leads to
reduction in measurable anti-HLA Class I antibody specificities
and may lead to a reduction in %PRA. There are associated
functional (mitogen responsiveness) and morphologic (T cell
subset [2]) changes suggesting down-regulation of the T cell
population. These changes may ultimately lead to a decrease in
the waiting time for a cadaveric renal allograft and may facili-
tate the immunologic success of the allograft. While these
studies require confirmation, the potential benefit that rHuEPO
may afford the dialysis and prospective renal transplant patient
is significant.
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